 |
Micah Feri (left) and Seema Tiwari-Woodruff. Photo Credit: Courtesy of University of California, Riverside |
Multiple sclerosis, or MS, is a chronic autoimmune disease affecting more than 2.9 million people worldwide. It occurs when the immune system mistakenly attacks the myelin sheath, the protective insulation around nerve fibers, causing disruption of nerve signals between the brain and body. Symptoms can include numbness, tingling, vision loss, and paralysis.
While current treatments can reduce inflammation, no therapies yet exist to protect neurons or restore the damaged myelin sheath. Researchers have now taken a major step forward in the development of such a therapy, supported by funding from the National Multiple Sclerosis Society. They have identified two compounds that could remyelinate damaged axons.
Published in the journal Scientific Reports, the research, led by Seema Tiwari-Woodruff, a professor of biomedical sciences at the University of California, Riverside, School of Medicine, and John Katzenellenbogen, a professor of chemistry at the University of Illinois Urbana-Champaign, or UIUC, was made possible through two National MS Society funding programs: a traditional investigator-initiated grant and the Society’s Fast Forward commercial accelerator program.